229 related articles for article (PubMed ID: 28133877)
1. Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis.
Bagherani N; Smoller BR
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28133877
[No Abstract] [Full Text] [Related]
2. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Ports WC; Khan S; Lan S; Lamba M; Bolduc C; Bissonnette R; Papp K
Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
[TBL] [Abstract][Full Text] [Related]
3. Small Molecules for Psoriasis.
Leonardi CL
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S65-6. PubMed ID: 27525564
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Kuo CM; Tung TH; Wang SH; Chi CC
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.
Hutmacher MM; Papp K; Krishnaswami S; Ito K; Tan H; Wolk R; Valdez H; Mebus C; Rottinghaus ST; Gupta P
CPT Pharmacometrics Syst Pharmacol; 2017 May; 6(5):322-330. PubMed ID: 28317328
[TBL] [Abstract][Full Text] [Related]
6. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
Strober B; Buonanno M; Clark JD; Kawabata T; Tan H; Wolk R; Valdez H; Langley RG; Harness J; Menter A; Papp K
Br J Dermatol; 2013 Nov; 169(5):992-9. PubMed ID: 23855761
[TBL] [Abstract][Full Text] [Related]
7. Oral tofacitinib for psoriasis: what happens with interrupted treatment?
Alinia H; Feldman SR
Br J Dermatol; 2015 May; 172(5):1194-5. PubMed ID: 25963217
[No Abstract] [Full Text] [Related]
8. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
Bissonnette R; Iversen L; Sofen H; Griffiths CE; Foley P; Romiti R; Bachinsky M; Rottinghaus ST; Tan H; Proulx J; Valdez H; Gupta P; Mallbris L; Wolk R
Br J Dermatol; 2015; 172(5):1395-406. PubMed ID: 25418186
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Papp KA; Krueger JG; Feldman SR; Langley RG; Thaci D; Torii H; Tyring S; Wolk R; Gardner A; Mebus C; Tan H; Luo Y; Gupta P; Mallbris L; Tatulych S
J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
[TBL] [Abstract][Full Text] [Related]
10. A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.
Callis Duffin K; Bushmakin AG; Cappelleri JC; Mallbris L; Mamolo C
BMC Dermatol; 2019 Jun; 19(1):8. PubMed ID: 31174539
[TBL] [Abstract][Full Text] [Related]
11. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
[TBL] [Abstract][Full Text] [Related]
13. Treatment of halo naevus with the topical Janus kinase inhibitor tofacitinib 1.5.
Hu WT; Lin FQ; Xu AE
Clin Exp Dermatol; 2018 Dec; 43(8):935-937. PubMed ID: 29876955
[No Abstract] [Full Text] [Related]
14. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Papp KA; Menter MA; Abe M; Elewski B; Feldman SR; Gottlieb AB; Langley R; Luger T; Thaci D; Buonanno M; Gupta P; Proulx J; Lan S; Wolk R;
Br J Dermatol; 2015 Oct; 173(4):949-61. PubMed ID: 26149717
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib for the treatment of lichen planopilaris: A case series.
Yang CC; Khanna T; Sallee B; Christiano AM; Bordone LA
Dermatol Ther; 2018 Nov; 31(6):e12656. PubMed ID: 30264512
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
[TBL] [Abstract][Full Text] [Related]
17. Systemics to topicals in psoriasis: the unfilled need.
Lingam P; Nwe S; Gordon KB
Br J Dermatol; 2013 Jul; 169(1):2-3. PubMed ID: 23834112
[No Abstract] [Full Text] [Related]
18. Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo.
Hayashi M; Okamura K; Abe Y; Hozumi Y; Suzuki T
J Dermatol; 2019 Jun; 46(6):548-550. PubMed ID: 30969438
[No Abstract] [Full Text] [Related]
19. Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
Griffiths CE; Vender R; Sofen H; Kircik L; Tan H; Rottinghaus ST; Bachinsky M; Mallbris L; Mamolo C
J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):323-332. PubMed ID: 27600367
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Gupta AK; Cernea M; Lynde CW
Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
